Orally active NGF synthesis stimulators: potential therapeutic agents in alzheimer's disease

Yamada, Kiyofumi; Nitta, Atsumi; Hasegawa, Takaaki; Fuji, Kazuyuki; Hiramatsu, Masayuki; Kameyama, Tsutomu; Furukawa, Yoshiko; Hayashi, Kyozo; Nabeshima, Toshitaka

doi:10.1016/s0166-4328(97)86054-8

Cited by 44 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These strategies include cholinesterase inhibition [47], M1 agonist administration [48], administration of nerve growth factor [49], estrogen replacement therapy [50], antioxidants, and antiinflammatory treatment [51][52]. More recently, new drug design has targeted molecular events involved in the pathogenesis of AD including β-amyloid and NFT formation [53][54][55].…”

Section: Heparin Oligosaccharides and Alzheimer's Disease Alzheimer'smentioning

confidence: 99%

Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia

Ma¹,

Cornelli²,

Hanin³

et al. 2007

CPD

View full text Add to dashboard Cite

Heparin is a glycosaminoglycan mixture currently used in prophylaxis and treatment of thrombosis. Heparin possesses non-anticoagulant properties, including modulation of various proteases, interactions with fibroblast growth factors, and anti-inflammatory actions. Senile dementia of Alzheimer's type is accompanied by inflammatory responses contributing to irreversible changes in neuronal viability and brain function. Vascular factors are also involved in the pathogenesis of senile dementia. Inflammation, endogenous proteoglycans, and assembly of senile plagues and neurofibrillary tangles contribute directly and indirectly to further neuronal damage. Neuron salvage can be achieved by anti-inflammation and the competitive inhibition of proteoglycans accumulation. The complexity of the pathology of senile dementia provides numerous potential targets for therapeutic interventions designed to modulate inflammation and proteoglycan assembly. Heparin and related oligosaccharides are known to exhibit antiinflammatory effects as well as inhibitory effects on proteoglycan assembly and may prove useful as neuroprotective agents.

show abstract

Section: Heparin Oligosaccharides and Alzheimer's Disease Alzheimer'smentioning

confidence: 99%

Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia

Ma¹,

Cornelli²,

Hanin³

et al. 2007

CPD

View full text Add to dashboard Cite

show abstract

“…34,35 Third, there is a neuronal plasticity, which counterbalances the degenerating process for a time, because the disease can be asymptomatic up to stage 6. One way to slow down the disease would be to boost the production of adequate trophic factors 36,37 (i.e. growth factors, cytokines, or neurosteroids) to stabilize vulnerable neuronal networks located along the pathway of NFD.…”

mentioning

confidence: 99%

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer’s disease

Thal¹,

Ferguson²,

Mintzer³

et al. 1999

Neurology

View full text Add to dashboard Cite

show abstract

“…Furthermore, this compound increases catecholamine and NGF content in the central nervous system of rats [13][14][15].…”

Section: Introductionmentioning

confidence: 92%

Solid State Cultivation of Hericium erinaceus Biomass and Erinacine: A Production

Gerbec

Gregori²,

Kreft³

et al. 2015

J Bioprocess Biotech

View full text Add to dashboard Cite

Hericium erinaceus is a medicinal mushroom producing biologically active metabolite erinacin A. In this research we compared fungal growth and metabolite production in different reactor types and different substrates with added casein peptone and NaCl. Cultivation of fungal biomass was performed in glass jars and horizontal stirred tank reactor. The cultivation in reactor was carried out at 24°C and airflow 5 L/min. Periodical mixing of N = 80 rpm, was used. Solid state substrate based on mixture of husked millet and paddy millet was used. For simultaneous determination of erinacine A and ergosterol contents in a single sample new analytical method was developed. The amount of biomass obtained in glass jars averaged at 100 mg/g ± 12 mg/g, while in horizontal mixing bioreactor it easily raised up to 350 mg/g. The highest erinacin A concentration was detected in substrate with 0.56% NaCl and 3.4% casein peptone content.

show abstract

Orally active NGF synthesis stimulators: potential therapeutic agents in alzheimer's disease

Cited by 44 publications

References 25 publications

Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia

Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer’s disease

Solid State Cultivation of Hericium erinaceus Biomass and Erinacine: A Production

Contact Info

Product

Resources

About